Synthesis and analgesic effects of 1-[1-(2-methylphenyl)(cyclohexyl)]-3-piperidinol as a new derivative of phencyclidine in mice

Abbas Ahmadi; Jalal Solati; Ramin Hajikhani; Masoud Onagh; Mojdeh Javadi

doi:10.1055/s-0031-1296317

Arzneimittelforschung, Table of Contents

Arzneimittelforschung 2010; 60(8): 492-496
DOI: 10.1055/s-0031-1296317

Analgesics · Anti-inflammatories · Antiphlogistics · Antirheumatic Drugs

Editio Cantor Verlag Aulendorf (Germany)

Synthesis and analgesic effects of 1-[1-(2-methylphenyl)(cyclohexyl)]-3-piperidinol as a new derivative of phencyclidine in mice

Abbas Ahmadi

¹Department of Chemistry, Faculty of Science, Islamic Azad University, Karaj branch, Karaj, Iran

,

Jalal Solati

²Department of Physiology, Islamic Azad University, Karaj Branch, Karaj, Iran

,

Ramin Hajikhani

²Department of Physiology, Islamic Azad University, Karaj Branch, Karaj, Iran

,

Masoud Onagh

¹Department of Chemistry, Faculty of Science, Islamic Azad University, Karaj branch, Karaj, Iran

,

Mojdeh Javadi

¹Department of Chemistry, Faculty of Science, Islamic Azad University, Karaj branch, Karaj, Iran

› Author Affiliations

Abstract

Phencyclidine (1-(1-phenylcyclohexyl) piperidine, CAS 956-90-1, PCP, I) and its derivatives have shown many analgesic effects. In this research, a new derivative of PCP (1-[1-(2-methylphenyl)(cyclohexyl)]-3-piperidinol, PD, II) was synthesized and its analgesic (acute and chronic pains) effects were examined on rats using tail immersion (as a model of acute thermal pain) and formalin (as a model of acute and chronic chemical pain) tests and the results are compared to PCP and control groups.

The results indicated that II produces higher analgesic effects in the tail immersion test compared to the PCP and control groups, with a marked and significant increase in tail immersion latency for the doses 1, 5 and 10 mg/kg. The formalin test showed that PD (II) is not effective in acute chemical pain (phase I, 0–5 min after injection) in all doses but chronic pain (initial-phase II, 15–40 min after injection) is significantly attenuated by this compound compared to PCP and saline (control) in doses of 5 and 10 mg/kg.

It is concluded that II is effective in acute thermal (in all doses) and chronic (doses of 5 and 10 mg/kg) pains; however, it is not effective in acute chemical pain compared to PCP and control.

Key words

Acute and chronic pain - Analgesics - CAS 956-90-1 - Formalin test - Phencyclidine, derivative - Tail immersion test

Full Text

References

References
1 Sattlegger M, Reissmüller E inventors; Grünenthal GmbH Aachen (DE), assignee. Substituted dimethyl-[1-(1-phenyl-cyclohexyl)-piperidin-3-ylmethyl]amines and the use of the same as analgesics. United States patent US 2004 0127516 A1. 2004.
2 Kamenka JM, Chiche B, Goudal R, Geneste P, Vignon J, Vincent JP et al. Chemical synthesis and molecular pharmacology of hydroxylated 1-[1-phenylcyclohexyl]piperi-dine derivatives. J Med Chem. 1982; 25: 431-5
3 Al-deeb OA.. Synthesis and analgesic activity of new phencyclidine derivatives. Arzneimittelforschung. 1994; 44 (10) 1141-4
4 Ahmadi A, Mahmoudi A. Synthesis and biological properties of 2-hydroxy-1-(1-phenyltetralyl)piperidine and some of its intermediates as derivatives of phencyclidine. Arzneimittelforschung. 2005; 55 (9) 528-32
5 Al-deeb OA. New analgesics derived from the phencyclidine analogue thienylcyclidine. Arzneimittelforschung. 1996; 46 ((I)) 505-508
6 Ahmadi A, Shafiezadeh M, Fathollahi Y, Darvich MR, Mahmoudi A, Bahmani M et al. Synthesis with improved yield and study on the analgesic effect of 2-hydroxyphencyclidine. Arzneimittelforschung. 2005; 55 (3) 172-6
7 Geneste P, Kamenka JM, Ung MSN, Herrmann P, Goudal R, Trouiller G. Determination conformationnelle de derives de la phencyclidine en vue d’une correlation structure-active. Eur J Med Chem Ther. 1979; 14: 301-8 French
8 Ahmadi A, Khalili M, Abbassi S, Javadi M, Mahmoudi A, Hajikhani R. Synthesis and study on analgesic effects of 1-[1-(4-methylphenyl)(cyclohexyl)]-4-piperidinol and 1-[1-(4-methoxyphenyl)[(cyclohexyl)]-4-piperidinol as two new phencyclidine derivatives. Arzneimittelforschung. 2009; 59 (4) 202-6
9 Ahmadi A, Khalili M, Mihandoust F, Barghi L. Synthesis and determination of acute and chronic pain activities of 1-[1-(3-methyphenyl)(tetralyl)]piperidine as a new derivative of phencyclidine via tail immersion and formalin tests. Arzneimittelforschung. 2010; 60 (1) 30-5
10 Medvedev IO, Malyshkin AA, Belozertseva IV, Sukhotina IA, Sevostianova NY, Aliev K et al. Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology. 2004; 47: 175-83
11 Honey CR, Miljkovic Z, MacDonald JF. Ketamine and phencyclidine cause a voltage-dependent block of responses to L-aspartic acid. Neurosci Lett. 1985; 61 ((1–2)) 135-9
12 Mozayani A. Phencyclidine – effects on human performance and behavior. Forensic Sci Rev. 2003; 15 (1) 62-74
13 Dougherty PM, Staats PS. Intrathecal drug therapy for chronic pain: from basic science to clinical practice. Anesthesiolog. 1999; 91: 1891-918
14 Johnson PY, Pan R, QuanWen J, Halfman CJ. Synthesis of amine derivatives of phencyclidine. J Org Chem. 1981; 46: 2049-54
15 Shebley M, Jushchyshyn MI, Hollenberg F. Selective pathways for the metabolism of phencyclidine by cytochrome P450 2B enzymes: identification of electrophilic methabolites, glutathione and N-acetyl cysteine adducts. Drug Metab Disp. 2006; 34 (3) 375-383
16 Maddox VH, Godefroi EF, Parcell RF. The synthesis of phencyclidine and other 1-arylcyclohexylamines. J Med Chem. 1965; 8: 230-5
17 Deleuze-Masquefa C, Michaud M, Vignon J, Kamenka JM. 1-[1-(2-Benzo[b]thiopheneyl]cyclohexyl]piperidine hydrochloride (BTCP) yields two active primary metabolites in vitro: synthesis, identification from rat liver microsome extracts affinity for the neuronal dopamine transporter. J Med Chem. 1997; 40: 4019-25
18 Hamura H, Yoshida M, Shimizu K, Matsukura T, Suzuki H, Narita M et al. Antinociceptive effect of the combination of pentazocine with morphine in the tail-immersion and scald-pain tests in rats. Jpn J Pharmacol. 2000; 83 (4) 286-92
19 Padi SSV, Kulkarni S. K. Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. Eur J Pharmacol. 2008; 601: 79-87
20 Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW et al. CB2 cannabinoid receptor mediation of antinociception. Pain. 2006; 122: 36-42
21 Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ -opioid-receptor gene. Nature. 1996; 383: 819-23
22 Hunter JC, Fontana DJ, Hedley LR, Jasper JR, Lewis R, Link RE et al. Assessment of the role of a 2-adrenoceptor sub type in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br J Pharmacol. 1997; 122: 1339-44
23 Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine and brain stem stimulation in rats and cats. Pain. 1977; 4 (2) 161-74
24 Moriarty RM, Enache LA, Zhao L, Gilardi R, Mattson MV, Prakash O. Rigid phencyclidine analogues: binding to the phencyclidine and sigma receptors. J Med Chem. 1998; 41: 468-77
25 Kamenka JM, Hamon J, Vignon J inventors; Societe de conseils de recherches et d’applications scientifiques (S.C.R.A.S.) (FR), assignee. Phencyclidine derivatives, preparation method and pharmaceutical compositions containing same. United States Patents US 6,342, 511B1. 2002
26 Nicholson KL, Balster RL. Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats. Psychopharmacology. 2003; 170: 215-24